Kenvue's stock is trading at $23.20, comfortably above key moving averages. The eight-day simple moving average sits at $22.33, the 20-day SMA is $21.87 and the 50-day SMA trails at $19.94.

Kenvue faces challenges with declining sales, cash flow risks, and high leverage. Read here for more analysis on KVUE stock.

Kenvue Inc . (NYSE:KVUE), the consumer health company spun off from Johnson & Johnson in 2023, finds itself at a critical juncture as it navigates its first full year as an independent entity.

Kenvue Inc. advanced stock charts by Barron's. View J4D historical stock data and compare to other stocks, and exchanges.

Shares for the Neutrogena-owner rose as much as 5.5% in premarket trading. Kenvue’s stock was up 8.2% this year through Wednesday’s close, far outstripping the 4.3% drop for the S&P 500 Index.

Shareholders of Kenvue Inc (Symbol: KVUE) looking to boost their income beyond the stock's 4% annualized dividend yield can sell the June covered call at the $22 strike and collect the premium ...

Johnson & Johnson named its consumer business Kenvue on Wednesday, moving ahead with its plans to spin-off the unit in what would be the biggest shake-up in the healthcare conglomerate's 135-year ...

Kenvue Inc. advanced stock charts by Barron's. View KVUE historical stock data and compare to other stocks, and exchanges.